NA
PLRX icon

NewEdge Advisors’s Pliant Therapeutics PLRX Stock Holding History

NewEdge Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1K Buy
+15,000
New +$18.3K ﹤0.01% 3403
2023
Q1 		– Sell
-35
Closed -$677 – 3953
2022
Q4 		$677 Buy
+35
New +$732 ﹤0.01% 3124

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

NewEdge Advisors's PLRX Position: Q2 2026 in Review

NewEdge Advisors opened a new position in Pliant Therapeutics (PLRX) in Q2 2026: 15,000 shares worth $17.1K. The stake represents ﹤0.01% of the portfolio and ranks #3403 among its holdings. This is a return to the name: NewEdge Advisors previously reported a position in PLRX as recently as Q4 2022.

NewEdge Advisors first reported a position in PLRX in Q4 2022 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • NewEdge Advisors held 15,000 shares of Pliant Therapeutics worth $17.1K as of Q2 2026.
  • Pliant Therapeutics was a new NewEdge Advisors position in Q2 2026.
  • Pliant Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3403 holding.
  • NewEdge Advisors first reported a position in Pliant Therapeutics in Q4 2022 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.